drugset / Trial / NCT04312113
Angiographic Delivery of AD-MSC for Ulcerative Colitis
NaSingle-groupOpen-labelTreatment
Summary
Researchers are trying to determine the safety and feasibility of using an adipose derived mesenchymal stem cell (MSC) to treat people with Ulcerative Colitis.
Timeline
- Start
- 2020-11-16
- Primary completion
- 2026-10
- Completion
- 2026-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AUTOLOGOUS ADIPOSE-DERIVED STROMAL VASCULAR FRACTION | Cell therapy | 15 cells | Other |
| Subject | AUTOLOGOUS ADIPOSE-DERIVED STROMAL VASCULAR FRACTION | Cell therapy | 30 cells | Other |